Biogen Idec: Tecfidera not cause of patient's death

Share this article:

Biogen Idec said the death of a patient in July was not caused by its MS drug Tecfidera, reported the Wall Street Journal, which says the patient's physician came to this conclusion.

The patient had taken Tecfidera but stopped her regimen two-and-a-half weeks before she died, due to side effects including vomiting and diarrhea. Biogen Idec told Pharmalot at the time that this was important to note because the death was not “GI related.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.